Additional file 10: of HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer

Kaplan-Meier survival estimates in patients from the BERGEN set who received no chemotherapy (untreated group, n  = 9) (a) or carboplatin-based chemotherapy (n  = 40) (b) and stratified according to HOTAIR expression. Patients (n = 49) treated in Bergen (Norway) and whose cancers had >25 % stroma component were analyzed; 8, 2, 34 and 5 had stage 1, 2, 3 and 4 disease, respectively; 32, 6, 9 and 2 had a serous, mucinous, endometrioid and clear cell cancer, respectively. In the untreated group, significantly more patients had stage 1 disease (44 % versus 10 % in the carboplatin group) and no residual disease after primary surgery (75 % versus 38 % in the carboplatin group). The top tertile expressing samples were deemed as high (positive) HOTAIR expressors and compared with low/absent (negative) HOTAIR expressors. There is no significant difference between high and low HOTAIR expressors with regards to grade, stage or residual disease. Comparing HOTAIR-positive with HOTAIR-negative patients, the hazard ratio is 2.55 (95 % confidence interval 1.14–5.68), P value 0.018. (PDF 244 kb)